Inxmed (nanjing) Co., Ltd.

Jiangwei Zhang

Zaiqi Wang

Jun Jiang

Baoyuan Zhang

Shuang Xie

A use of a FAK inhibitor in the preparation of a drug for preventing and/or treating tumors having an NRAS mutation. A method for treating tumors that have experienced an NRAS mutation, which comprises administering an effective dose of a FAK inhibitor to an individual. A FAK inhibitor for treating tumors having an NRAS mutation. The FAK inhibitor is B1853520, defactinib, GSK2256098, PF-00562271, VS-4718 or a pharmaceutically acceptable salt thereof.

Use of FAK inhibitor in preparation of drug for treating tumors having NRAS mutation

The present invention relates to a method for treating a tumor with a KRAS mutation. In the method, a compound 2-fluoro-5-methoxy-4-[(4-(2-methyl-3-oxo-2,3-dihydro-1H-isoindole-4-oxy)-5-trifluoromethyl-pyrimidine-2-yl)amino]-N-(1-methyl-piperidine-4-yl)benzamide or a pharmaceutically acceptable salt thereof is used, which can be administered alone or in combination with a KRAS inhibitor and/or an MEK inhibitor.

Use of BI853520 in cancer treatment

The present invention relates to the combined use of: (a) the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) PLD or a pharmaceutically acceptable salt thereof, for treating ovarian cancer.

Combined use of IN10018 and PLD

The present invention relates to a use of BI853520 or a pharmaceutically acceptable salt thereof in preparing drugs for treating tumors in combination with chemotherapeutic drugs.

Combination of BI853520 with chemotherapeutic drugs

The present invention relates to a method for treating a tumor with a KRAS mutation. In the method, a compound 2-fluoro-5-methoxy-4-[(4-(2-methyl-3-oxo-2,3-dihydro-1H-isoindole-4-oxy)-5-trifluoromethyl-pyrimidine-2-yl)amino]-N-(1-methyl-piperidine-4-yl)benzamide or a pharmaceutically acceptable salt thereof is administered in combination with a KRAS inhibitor or an MEK inhibitor.

Growing community of inventors

Shanghai, China

Jiangwei Zhang